Loading…
Zentalis Pharmaceuticals, Inc. is projected to rise to $6.93 by 2027, a +46% move from its current price of $4.74. ZNTL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 3 | $4.54 | $4.74 | $4.94 | -0.01% |
| Aug 4 | $4.46 | $4.74 | $5.03 | -0.03% |
| Aug 5 | $4.40 | $4.74 | $5.10 | -0.04% |
| Aug 6 | $4.35 | $4.74 | $5.15 | -0.06% |
| Aug 7 | $4.31 | $4.74 | $5.20 | -0.07% |
| Aug 8 | $4.27 | $4.74 | $5.25 | -0.08% |
| Aug 9 | $4.24 | $4.74 | $5.29 | -0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.24 | $4.74 | $5.29 | -0.10% |
| Week 2 | $4.04 | $4.73 | $5.54 | -0.19% |
| Week 3 | $3.90 | $4.73 | $5.73 | -0.29% |
| Week 4 | $3.78 | $4.72 | $5.90 | -0.39% |
| Week 5 | $3.68 | $4.72 | $6.05 | -0.48% |
| Week 6 | $3.59 | $4.71 | $6.19 | -0.58% |
| Week 7 | $3.51 | $4.71 | $6.32 | -0.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc.
was incorporated in 2014 and is based in San Diego, California.
Zentalis Pharmaceuticals, Inc. is a biotech stock with a current price of $4.92 and a market cap of $350.24M. Its rank is 3150 in market capitalization.
The current price and market cap frame a relatively small-position biotechnology asset, with a long-run forecast reflecting a path higher in subsequent years. The 2026 forecast shows an avg price of $4.92 with a 0% ROI and neutral sentiment, followed by bullish projections in later years (e.g., 2027 avg $7.21; 2030 avg $8.43; 2040 avg $22.13; 2050 avg $32.32) as the potential upside expands.
A major floor 55.7% below — a decisive break under it would weaken the trend.
The nearest floor, 22.6% below — buyers have tended to step in here.
The nearest ceiling, 7.8% above — a clean break opens room to run.
A major ceiling 39.5% above — clearing it would confirm fresh momentum.
Key ZNTL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZNTL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.69 | Buy | $4.72 | Buy |
| MA 10 | $4.68 | Buy | $4.69 | Buy |
| MA 20 | $4.73 | Buy | $4.62 | Buy |
| MA 50 | $4.23 | Buy | $4.34 | Buy |
| MA 100 | $3.92 | Buy | $3.90 | Buy |
| MA 200 | $2.93 | Buy | $3.35 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.19 | Neutral |
| Stoch RSI (14) | 43.59 | Neutral |
| CCI (20) | 5.26 | Neutral |
| Williams %R (14) | -47.44 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -0.84 | Sell |
| Bollinger %B (20,2) | 0.52 | Neutral |
| Stochastic %K (14) | 52.56 | Neutral |
| TRIX (15) | 0.54 | Buy |
| Awesome (5,34) | 0.27 | Buy |
| Ultimate (7,14,28) | 59.36 | Neutral |
| Momentum (10) | -0.37 | Sell |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 4.82 | Sell |
| ADX (14) | 13.13 | Neutral |
| ATR (14) | 0.18 | Info |
The 30-day technical picture remains bullish overall. RSI14 is 60, and the short-term trend is supported by a SMA50 of $4.21 and a SMA200 of $2.92.
Support is at $3.62 and resistance at $5.11, providing a defined trading range. The 30-day price range runs from a low of $3.71 to a high of $6.52, framing within which near-term movements may unfold.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.37 | $4.74 | $6.28 | 0% | Neutral | |
| $5.26 | $6.93 | $9.81 | +46% | Bullish | |
| $5.51 | $7.61 | $11.37 | +61% | Bullish | |
| $4.99 | $7.17 | $11.16 | +51% | Bullish | |
| $5.49 | $8.16 | $13.15 | +72% | Bullish | |
| $5.41 | $8.30 | $13.78 | +75% | Bullish | |
| $5.56 | $8.80 | $14.99 | +86% | Bullish | |
| $7.16 | $11.65 | $20.32 | +146% | Bullish | |
| $8.02 | $13.41 | $23.90 | +183% | Bullish | |
| $8.40 | $14.43 | $26.24 | +204% | Bullish | |
| $11.22 | $21.83 | $43.11 | +361% | Bullish | |
| $14.43 | $32.07 | $71.18 | +577% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.37 | $4.74 | $5.54 | +0.00% |
| September 2026 | $3.67 | $4.41 | $5.50 | -6.91% |
| October 2026 | $3.85 | $4.68 | $5.93 | +6.07% |
| November 2026 | $3.97 | $4.87 | $6.25 | +4.01% |
| December 2026 | $3.92 | $4.84 | $6.28 | -0.58% |
Click any year to see its month-by-month ZNTL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, ZNTL could reach as high as $6.28, with a base case around $4.74 and support toward $1.37 — roughly 0% from $4.74. A consolidation phase looks the most probable path here.
Expect ZNTL to range from $5.26 to $9.81 through 2027. The $6.93 average target implies a +46% move from current prices. That is up +46% on the projected 2026 average. Momentum favours further upside here.
The ZNTL price prediction for 2028 points to an average of $7.61 (low $5.51, high $11.37) — a potential gain of +61% on today's $4.74. Buyers look set to stay in control over this stretch.
In 2029, ZNTL is projected to trade between $4.99 and $11.16, averaging $7.17 — a potential gain of +51% from today's $4.74. That is -6% versus the projected 2028 average. Momentum favours further upside here.
Zentalis Pharmaceuticals, Inc.'s 2030 outlook centres on $8.16, within a $5.49 to $13.15 range. That is up +14% on the projected 2029 average. That marks a +72% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, ZNTL could reach as high as $13.78, with a base case around $8.30 and support toward $5.41 — roughly +75% from $4.74. Momentum favours further upside here.
Expect ZNTL to range from $5.56 to $14.99 through 2032. The $8.80 average target implies a +86% move from current prices. That is up +6% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The ZNTL price prediction for 2033 points to an average of $11.65 (low $7.16, high $20.32) — a potential gain of +146% on today's $4.74. Momentum favours further upside here.
In 2034, ZNTL is projected to trade between $8.02 and $23.90, averaging $13.41 — a potential gain of +183% from today's $4.74. That is up +15% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Zentalis Pharmaceuticals, Inc.'s 2035 outlook centres on $14.43, within a $8.40 to $26.24 range. That is up +8% on the projected 2034 average. That marks a +204% change versus current levels. Momentum favours further upside here.
By 2040, ZNTL could reach as high as $43.11, with a base case around $21.83 and support toward $11.22 — roughly +361% from $4.74. Buyers look set to stay in control over this stretch.
Expect ZNTL to range from $14.43 to $71.18 through 2050. The $32.07 average target implies a +577% move from current prices. That is up +47% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ZNTL today (≈ 210.970464 ZNTL) could be worth
$6,765.02
+$5,765.02 (+577%) by 2050 · US Dollar
Based on the average projected ZNTL price of $32.07 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZNTLwould be worth at today's price.
$1,000 invested in ZNTL on Jul 31, 2025 (≈ 724.637684 ZNTL) would be worth
$3,434.78
+$2,434.78 (+243.5%) today · 3.43× · US Dollar
Based on a ZNTL entry price of $1.38 vs. today's $4.74.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.33 | $1,094.69 | +9.5% |
| 1 month ago | $4.36 | $1,088.4 | +8.8% |
| 3 months ago | $4.09 | $1,158.92 | +15.9% |
| 6 months ago | $2.51 | $1,888.45 | +88.8% |
| 1 year ago | $1.38 | $3,434.78 | +243.5% |
| All time (5.0y) ago | $51.28 | $92.43 | -90.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZNTL forecast.
Our base-case forecast reaches $9.50 around 2033.
Implied market cap at $9.50: $676.27M
Over the multi-year horizon, the forecast shows a bullish trajectory with rising averages and sizable ROIs. The 2030 forecast lists an avg of $8.43 with a 71.3% ROI, and a bullish sentiment; the 2040 forecast lists an avg of $22.13 with a 349.8% ROI, also bullish; and the 2050 forecast lists an avg of $32.32 with a 557% ROI, continuing the bullish tone.
Maximal forecast values illustrate greater upside, with 2033 max $20.99, 2040 max $43.98, and 2050 max $72.30, all labeled bullish. In this long horizon, the landscape shows substantial upside potential relative to the current price, though these figures are estimates and not guarantees. Maintain awareness that actual results may differ and depend on future developments in the company’s programs and market conditions.
Tap a question to reveal the answer.
2030 min $5.64, avg $8.43, max $13.63, ROI 71.3, sentiment BULLISH.
The 2026 forecast shows avg $4.92 with ROI 0 and sentiment NEUTRAL. Longer-term years show bullish sentiment with higher averages and ROIs, but forecasts are not guarantees.
Yes. The forecast max values exceed $10 in multiple years: 2030 max $13.63 and 2033 max $20.99.
2030 avg $8.43 (ROI 71.3%, bullish); 2040 avg $22.13 (ROI 349.8%, bullish); 2050 avg $32.32 (ROI 557%, bullish). Maxima include 2033 $20.99, 2040 $43.98, 2050 $72.30.
Current price $4.92; market cap $350.24M; rank 3150.
Zentalis Pharmaceuticals, Inc. Community Discussion
0Share your Zentalis Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.